Date Filed | Type | Description |
08/16/2023 |
4
| PASSERI DANIEL R (CEO) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Bought 3,000 shares
@ $2.86, valued at
$8.6k
|
|
07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/25/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/25/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
04/21/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/13/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
04/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
03/27/2023 |
4
| Kiener Peter A (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Sold 9,325 shares
@ $3.28, valued at
$30.6k
Exercised 9,682 options to buy
@ $2.86, valued at
$27.7k
|
|
02/21/2023 |
4
| NASSHORN PATRICIA (Chief Business Officer) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 97,900 options to buy
@ $3.21, valued at
$314.3k
|
|
02/21/2023 |
4
| Suri Anish (PRESIDENT AND CSO) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 125,500 options to buy
@ $3.21, valued at
$402.9k
|
|
01/19/2023 |
4
| Levisetti Matteo (Chief Medical Officer) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 110,000 options to buy
@ $3.36, valued at
$369.6k
|
|
01/19/2023 |
3
| Levisetti Matteo (Chief Medical Officer) has filed a Form 3 on Cue Biopharma, Inc. |
01/05/2023 |
4
| Morich Frank (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
01/05/2023 |
4
| Kiener Peter A (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
01/05/2023 |
4
| HOWSON TAMAR D (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
01/05/2023 |
4
| Fletcher Aaron G.L. (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
01/05/2023 |
4
| DRISCOLL FREDERICK W (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 10,000 options to buy
@ $2.66, valued at
$26.6k
|
|
08/23/2022 |
4
| Millar Kerri-Ann (CFO) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Paid exercise price by delivering 2,828 shares
@ $3.05, valued at
$8.6k
Exercised 6,667 restricted stock units
@ $0 |
|
06/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/31/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/25/2022 |
4
| Fletcher Aaron G.L. (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Bought 150,000 shares
@ $3.52, valued at
$528k
Bought 55,000 shares
@ $3.34, valued at
$183.7k
|
|
04/04/2022 |
4
| Suri Anish (PRESIDENT AND CSO) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Paid exercise price by delivering 7,068 shares
@ $4.88, valued at
$34.5k
Exercised 16,668 restricted stock units
@ $0 |
|
04/04/2022 |
4
| PASSERI DANIEL R (CEO) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Paid exercise price by delivering 32,122 shares
@ $4.88, valued at
$156.8k
Gifted 10,000 shares
@ $0 Exercised 75,000 restricted stock units
@ $0 |
|
04/04/2022 |
4
| Fletcher Aaron G.L. (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Bought 735,000 shares
@ $4.76, valued at
$3.5M
|
|
03/29/2022 |
4
| NASSHORN PATRICIA (Chief Business Officer) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 10,000 options to buy
@ $5.01, valued at
$50.1k
|
|
03/29/2022 |
4
| Suri Anish (PRESIDENT AND CSO) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 82,000 options to buy
@ $6.91, valued at
$566.6k
Granted 21,333 options to buy
@ $5.01, valued at
$106.9k
|
|
03/29/2022 |
4
| Sandercock Colin (SVP, GENERAL COUNSEL) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 60,000 options to buy
@ $6.91, valued at
$414.6k
Granted 16,667 options to buy
@ $5.01, valued at
$83.5k
|
|
03/29/2022 |
4
| Pienta Kenneth (Chief Medical Officer) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 40,000 options to buy
@ $5.01, valued at
$200.4k
|
|
03/29/2022 |
4
| PASSERI DANIEL R (CEO) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 100,000 options to buy
@ $5.01, valued at
$501k
|
|
03/29/2022 |
4
| Millar Kerri-Ann (CFO) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 85,000 options to buy
@ $6.91, valued at
$587.4k
Granted 10,000 options to buy
@ $5.01, valued at
$50.1k
|
|
01/05/2022 |
4
| Fletcher Aaron G.L. (Director) has filed a Form 4 on Cue Biopharma, Inc.
Txns:
| Granted 10,000 options to buy
@ $12.28, valued at
$122.8k
|
|
|